Does the Term “Deflators” Reflect More Accurately the Beneficial Effects of Long-acting Bronchodilators in COPD?

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 13, Issue 5, 2016, Pages 537-539

  Kostikas, Konstantinos ^a,b   Siafakas, Nikolaos M ^c  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF CRETE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT;

ANTIINFLAMMATORY ACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG EFFECT; DYSPNEA; EDITORIAL; EXERCISE; HUMAN; INSPIRATORY CAPACITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; DELAYED RELEASE FORMULATION; DRUG EFFECTS; LUNG; NOMENCLATURE; PATHOPHYSIOLOGY;

BRONCHODILATOR AGENTS; DELAYED-ACTION PREPARATIONS; HUMANS; LUNG; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TERMINOLOGY AS TOPIC;

EID: 84983334759     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2016.1153615     Document Type: Editorial

References (31)

1. B.R.Celli, W.MacNee, A.E.T.Force. Standards for the diagnosis and treatment of patients with COPD:a summary of the ATS/ERS position paper. Eur Respir J 2004; 23(6):932–946.
2. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD, 2014. Available from http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html (accessed 21 November 2015).
3. P.J.Barnes Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol 2008; 8(3):183–192.
4. A.P.Greening, P.W.Ind, M.Northfield, G.Shaw. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994; 344(8917):219–224.
5. M.Johnson Interactions between corticosteroids and beta2-agonists in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 2004; 1(3):200–206.
6. K.F.Rabe Improving dyspnea in chronic obstructive pulmonary disease:optimal treatment strategies. Proc Am Thorac Soc 2006; 3(3):270–275.
7. A.Agusti, P.M.Calverley, B.Celli, H.O.Coxson, L.D.Edwards, D.A.Lomas, Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010; 11:122.
8. M.Cazzola, K.M.Beeh, D.Price, N.Roche. Assessing the clinical value of fast onset and sustained duration of action of long-acting bronchodilators for COPD. Pulm Pharmacol Ther 2015; 31:68–78.
9. A.Rossi, Z.Aisanov, S.Avdeev, G.Di Maria, C.F.Donner, J.L.Izquierdo, Mechanisms, assessment and therapeutic implications of lung hyperinflation in COPD. Respir Med 2015; 109(7):785–802.
10. J.Macklem PT. Therapeutic implications of the pathophysiology of COPD. Eur Respir 2010; 35(3):676–680.
11. D.E.O'Donnell, P.Laveneziana. The clinical importance of dynamic lung hyperinflation in COPD. COPD 2006; 3(4):219–232.
12. D.E.O'Donnell, C.M.Parker. COPD exacerbations. 3:Pathophysiology. Thorax 2006; 61(4):354–361.
13. C.M.Parker, N.Voduc, S.D.Aaron, K.A.Webb, D.E.O'Donnell. Physiological changes during symptom recovery from moderate exacerbations of COPD. Eur Respir J 2005; 26(3):420–428.
14. M.F.Newton, D.E.O'Donnell, L.Forkert. Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. Chest 2002; 121(4):1042–1050.
15. D.E.O'Donnell, M.Lam, K.A.Webb. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160(2):542–549.
16. B.Celli, R.ZuWallack, S.Wang, S.Kesten. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003; 124(5):1743–1748.
17. D.E.O'Donnell, T.Fluge, F.Gerken, A.Hamilton, K.Webb, B.Aguilaniu, Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23(6):832–840.
18. K.M.Beeh, S.Korn, J.Beier, D.Jadayel, M.Henley, P.D'Andrea, Effect of QVA149 on lung volumes and exercise tolerance in COPD patients:the BRIGHT study. Respir Med 2014; 108(4):584–592.
19. K.M.Beeh, D.Singh, L.Di Scala, A.Drollmann. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD:the GLOW3 trial. Int J Chron Obstruct Pulmon Dis 2012; 7:503–513.
20. F.Maltais, A.Hamilton, D.Marciniuk, P.Hernandez, F.C.Sciurba, K.Richter, Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest 2005; 128(3):1168–1178.
21. M.Thomas, M.Decramer, D.E.O'Donnell. No room to breathe:the importance of lung hyperinflation in COPD. Prim Care Respir J 2013; 22(1):101–111.
22. D.Tashkin, B.Celli, M.Decramer, D.Liu, D.Burkhart, C.Cassino, Bronchodilator responsiveness in patients with COPD (data from the UPLIFT trial). Rev Port Pneumol 2008; 14(4):584–587.
23. J.A.Wedzicha, M.Decramer, J.H.Ficker, D.E.Niewoehner, T.Sandstrom, A.F.Taylor, Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK):a randomised, double-blind, parallel-group study. Lancet Respir Med 2013; 1(3):199–209.
24. J.Vestbo, P.Lange. Prevention of COPD exacerbations:medications and other controversies. ERJ Open Res 2015, doi:10.1183/23120541.00011-2015 Published 6 May 2015.
25. P.Santus, D.Radovanovic, S.Di Marco, V.Valenti, R.Raccanelli, F.Blasi, Effect of indacaterol on lung deflation improves cardiac performance in hyperinflated COPD patients:an interventional, randomized, double-blind clinical trial. Int J Chron Obstruct Pulmon Dis 2015; 10:1917–1923.
26. C.Casanova, C.Cote, J.P.de Torres, A.Aguirre-Jaime, J.M.Marin, V.Pinto-Plata, Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 171(6):591–597.
27. B.Celli, M.Decramer, S.Kesten, D.Liu, S.Mehra, D.P.Tashkin, Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180(10):948–955.
28. P.R.Burgel, J.L.Paillasseur, D.Dusser, N.Roche, D.Liu, Y.Liu, Tiotropium might improve survival in subjects with COPD at high risk of mortality. Respir Res 2014; 15:64.
29. E.D.Bateman, G.T.Ferguson, N.Barnes, N.Gallagher, Y.Green, M.Henley, Dual bronchodilation with QVA149 versus single bronchodilator therapy:the SHINE study. Eur Respir J 2013; 42(6):1484–1494.
30. M.Decramer, A.Anzueto, E.Kerwin, T.Kaelin, N.Richard, G.Crater, Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease:results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med 2014; 2(6):472–486.
31. R.Buhl, F.Maltais, R.Abrahams, L.Bjermer, E.Derom, G.Ferguson, Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur Respir J 2015; 45(4):969–979.